{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Alfentanil in Hysteroscopic Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "One hundred and forty female patients, ASA grade I or II, aged 18\u201365 years, scheduled for hysteroscopy at Women\u2019s Hospital, Zhejiang University, were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "One hundred and forty female patients, ASA grade I or II, aged 18\u201365 years, scheduled for hysteroscopy at Women\u2019s Hospital, Zhejiang University"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive 8 \u00b5g\u00b7kg\u22121, 10 \u00b5g\u00b7kg\u22121, 12 \u00b5g\u00b7kg\u22121, 14 \u00b5g\u00b7kg\u22121 alfentanil, or 0.15 \u00b5g\u00b7kg\u22121 sufentanil"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to determine the median effective dose (ED50) and the 95% effective dose (ED95) of alfentanil"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the ED50 and ED95 of alfentanil, measured using probit analysis"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated and allocation was concealed in sealed envelopes"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, outcome assessors, and clinicians"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "One hundred and forty female patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ED50 and ED95 of alfentanil were 9.73 \u00b5g\u00b7kg\u22121 (95% CI 8.57 to 10.56) and 15.02 \u00b5g\u00b7kg\u22121 (95% CI 13.57 to 18.12), respectively"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were less frequent in the 10\u201312 \u00b5g\u00b7kg\u22121 groups compared to sufentanil"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ChiCTR2400080232"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}